drugset
drugset / Trial / NCT01704482

N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

NCT01704482 ↗

Phase 2 Completed 60 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

Timeline

Start
2011-02
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 100 mg/kg Intravenous

Indications

impaired renal function disease rheumatic heart disease